Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Completed
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 2
2003-05-01
Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and
damages brain cells. The clot, or thrombus, is made up of platelets and fibrin. The medicine
alteplase, also known as tPA , is the standard drug used to treat patients with acute
ischemic stroke. tPA attacks the fibrin portion of the blood clot. While intravenous (iv) tPA
alone is effective in treating the fibrin part of the clot approximately 30% of the time,
adding other commercially available drugs such eptifibatide to treat other clot components
may improve the effectiveness of iv tPA therapy.
This is a clinical trial to determine an acceptable dose of eptifibatide in combination with
aspirin, the low molecular weight heparin tinzaparin, and standard iv tPA therapy for the
treatment of acute ischemic stroke. Use of clinical and imaging based selection criteria are
hypothesized to contribute to treatment safety by selecting patients at lower risk of
intracerebral hemorrhage. Also,selection and evaluation of patients by magnetic resonance
imaging (MRI) criteria will result in a different risk to benefit ratio than selecting
patients without MRI criteria and will lead to a different acceptable dose.
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Completed
Duke Clinical Research Institute
Phase 3
2004-11-01
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients
with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death,
heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed
provisional use of eptifibatide).
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2004-11-01
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients
with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death,
heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed
provisional use of eptifibatide).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
